Cholinergic System

The quaternary nitrogen is essential. Look at the Acetylcholine structure — the N⁺ bearing three methyl groups is non-negotiable. Molecular modeling shows it binds to a negatively charged aspartate residue (Asp⁻) in the receptor. Replacing N with As, P, or S → massive loss of activity. At minimum, two methyl groups on the nitrogen are required. Larger alkyl groups (ethyl, propyl) or replacing all methyls with H → inactive.

The ethylene bridge (2 carbons) is the perfect distance. The 2-carbon spacer between N⁺ and the ester oxygen is critical. Shorter (1 carbon) or longer (3+ carbons) chains → reduced activity. This distance optimally positions the cationic head to bind the receptor while the ester reaches its H-bonding site.

β-Methyl = steric shield + muscarinic selectivity. Look at Methacholine — the methyl on the β-carbon (closest to oxygen) physically blocks esterases from accessing the ester bond. The β-position is more effective than the α-position for blocking hydrolysis. Bonus: this substitution also confers muscarinic selectivity over nicotinic.

Carbamate replaces ester = resistance to hydrolysis. Compare Carbachol with Acetylcholine. The only change: –OCOCH₃ → –OCONH₂. The NH₂ and CH₃ are bioisosteres (same size), so receptor binding is maintained. But the carbamate is far more resistant to esterase hydrolysis → much longer duration.

Combine both modifications for the ideal drug. Bethanechol = carbamate (stable) + β-methyl (muscarinic selective). This gives a drug that is: orally active, stable, and selective for muscarinic receptors. Used clinically to stimulate GIT and bladder smooth muscle after surgery.

The Five-Atom Rule. For maximal muscarinic activity, the quaternary ammonium should be followed by a chain of exactly 5 atoms (N⁺—C—C—O—C=O—X). Count the atoms in Acetylcholine: from N⁺ to the terminal methyl carbon of the acetyl = 5 atoms. Bigger acyl groups (propionyl, butyryl) reduce potency.

Aromatic esters flip the activity. Replacing the small acetyl group with an aromatic ring (benzoyl ester) doesn't just reduce agonist activity — it converts the molecule into a cholinergic antagonist. This is a key insight: bulky lipophilic groups near the ester create blockers, not activators.

Cationic head: tertiary or quaternary N. Unlike agonists (which need quaternary N with small methyls), antagonists allow larger alkyl groups on nitrogen — methyl, ethyl, propyl, or isopropyl all work. This is a key difference from agonists. Making it quaternary (like Ipratropium) prevents BBB crossing → eliminates CNS side effects but limits to peripheral actions only.

The chain/linker: ester preferred but not essential. An ester linkage gives the best potency (better receptor binding through H-bonding). However, the linker can also be an ether, a simple hydrocarbon chain, or even absent entirely. A hydroxyl group on the chain increases antimuscarinic activity but is not required. Ideal spacer is still 2 CH₂ units between the bulky end and the nitrogen.

Bulky cyclic groups (A, B) are what make it a blocker. Look at Atropine — see the phenyl ring? That's the bulky group that physically blocks the receptor without activating it. Antagonists need at least one (preferably two) large groups: aromatic rings, cycloalkyl rings, or heteroaromatic rings. These create van der Waals interactions with the non-polar binding pocket. Remember: aromatic esters on the agonist template convert it to an antagonist!

Quaternary N = no CNS effects. Compare Atropine (tertiary N, crosses BBB → causes confusion, dry mouth, hallucinations) with Ipratropium (quaternary N, fully ionized → cannot cross BBB). Quaternary analogues are used when you want peripheral effects only (e.g., bronchodilation without cognitive impairment).

Two cationic centers at the right distance. Look at Tubocurarine — it has two quaternary nitrogen atoms separated by a rigid molecular scaffold (~1.09 nm apart). This distance matches the spacing of the two anionic binding sites on the nicotinic receptor. All effective neuromuscular blockers maintain this dual-cation motif.

Ester bonds = shorter duration. Compare Suxamethonium (two ester bonds → hydrolyzed in ~5 min) with Tubocurarine (no esters → long duration). Incorporating ester linkages into the spacer between the two N⁺ centers allows plasma esterases to rapidly break down the drug → faster recovery from paralysis.

Suxamethonium = two ACh molecules back-to-back. Look at the Suxamethonium structure. It's literally two acetylcholine skeletons connected at their acetyl ends via a succinate linker. This “bis-ACh” design gives it affinity for both anionic sites. Ultra-short acting because plasma esterases attack the ester bonds rapidly.

Hofmann elimination: self-destruct at blood pH. Atracurium was designed with a clever trick: at acid pH (storage) it's stable, but at blood pH (7.4) it undergoes spontaneous Hofmann elimination — a non-enzymatic chemical degradation. This means its breakdown doesn't depend on liver or plasma enzymes → no patient variability in metabolism.

Mivacurium: no Hofmann, but faster. Mivacurium lacks the structural feature needed for Hofmann elimination (no β-hydrogen adjacent to the quaternary N in the right geometry). Instead, it's metabolized by plasma cholinesterases. Despite this, it has faster onset (2 min) and shorter duration (15 min) than atracurium.

The carbamate is essential. Look at the Physostigmine structure — the methylcarbamate group (–OCONH–CH₃) is what inhibits AChE. It carbamylates the serine residue in the active site, just like ACh acetylates it. But the carbamyl-enzyme intermediate takes 10⁷ times longer to hydrolyze than the acetyl-enzyme → enzyme is effectively blocked for minutes instead of microseconds.

Carbamate stability hierarchy. The order of stability (and thus inhibition duration) is: –OCONH₂ > –OCONHCH₃ > –OCON(CH₃)₂. Wait — that seems backwards for clinical use. Actually, greater chemical stability of the carbamate = longer-lasting enzyme inhibition. Neostigmine uses dimethylcarbamate for this reason.

The benzene ring and pyrrolidine ring are important. In Physostigmine, the benzene ring helps position the molecule in the active site gorge, and the pyrrolidine nitrogen (protonated at blood pH) mimics the quaternary N of ACh to bind the anionic site of AChE.

Quaternary vs tertiary N: CNS access. Compare Neostigmine (quaternary N → cannot cross BBB → peripheral use only) with Rivastigmine (tertiary N → crosses BBB → treats Alzheimer's in the CNS). Choose based on where you need the drug to act.

Phosphorylation instead of carbamylation. Organophosphates transfer a phosphoryl group to the AChE serine (same serine that gets acetylated by ACh and carbamylated by physostigmine). But unlike carbamyl or acetyl intermediates, the phosphoryl-enzyme bond is essentially permanent — it doesn't hydrolyze on any clinically relevant timescale.

The “A” atom determines activation. In organophosphates (general structure: R₁R₂–P(=A)–X), “A” is usually oxygen or sulfur. When A = sulfur (as in many insecticides like malathion), the compound requires metabolic activation (P=S → P=O conversion by liver enzymes) before becoming an effective AChE inhibitor. This gives a margin of safety — mammals detoxify these faster than insects.

Insecticides exploit species differences. Compounds like malathion are poor inhibitors of human cholinesterases in their native form. Mammals rapidly inactivate them via hydrolysis. Insects metabolize them differently → the toxic P=O form accumulates → selective insect toxicity. This is why they're “safe” insecticides (relatively).

Pralidoxime: reactivation by nucleophilic attack. Look at the Pralidoxime structure — the oxime group (=N–OH) is a powerful nucleophile. It attacks the phosphorus atom on the phosphorylated enzyme, breaking the P–O–Serine bond and regenerating active AChE. Time-critical: after “aging” (loss of one alkyl group from phosphorus), the enzyme can no longer be reactivated.